Decrease size
Reset to Default
Increase size

Proposal Number: 4192

Domain: Healthcare

Theme(s): Trauma and Accidents Care

Supporting Central Government Agency:

Budget (Rs. Lakhs): 99.60

Principal Investigator: Tapan Kumar Chaudhuri

Principal Investigator Institute: Indian Institute of Technology -Delhi

Co-Investigators:
Prof. K. J. Mukherjee ,Jawahar Lal Nehru University, Delhi
Prof. Amit Kumar Dinda ,All Indian Institute of Medical Science

Domain: Healthcare

Project Title

Production of a crucial therapeutic protein for Trauma and Accident care in Escherichia Coli system

Web Abstract

Trauma remains a significant public health issue becoming the leading cause of death. Human serum albumin is the prime therapeutic protein administered in the patients suffering from it. Currently, HSA is primarily obtained from the fractionation of collected human blood, which is a limited and unsafe source possessing the risk of contamination by blood derived pathogens. Thus there exists an indispensable need to promote non animal derived rHSA production. Considering the availability of various FDA approved recombinant therapeutics produced in E. coli system, rHSA production using the same host can be of significant benefit for the desired applications. In this project we are proposing for enhancement of functional rHSA production in the very well-studied, scalable, fast growing and convenient expression host system, i.e. E. coli through recombinant DNA technology. Hence, developing an E. coli based system to prepare immensely important, multi-application oriented recombinant therapeutic protein like HSA is truly important and immensely demand driven.